{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:00:12Z","timestamp":1790305212444,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["H2023147"],"award-info":[{"award-number":["H2023147"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Epidemiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.annepidem.2026.110096","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:25:27Z","timestamp":1775841927000},"page":"110096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Longitudinal atherogenic index of plasma trajectories and risk of MASLD progression: A large retrospective cohort study"],"prefix":"10.1016","volume":"119","author":[{"given":"Ningning","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-2149","authenticated-orcid":false,"given":"Jinshun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.annepidem.2026.110096_bib2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","article-title":"An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.annepidem.2026.110096_bib4","article-title":"The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.annepidem.2026.110096_bib5","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1016\/j.cgh.2021.01.030","article-title":"Trends in the prevalence of metabolic dysfunction-associated fatty liver disease in the United States, 2011-2018","volume":"20","author":"Wong","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"18","key":"10.1016\/j.annepidem.2026.110096_bib6","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"10.1016\/j.annepidem.2026.110096_bib7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: An update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110096_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0009-9120(01)00263-6","article-title":"The plasma parameter log (TG\/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL))","volume":"34","author":"Dobiasova","year":"2001","journal-title":"Clin Biochem"},{"issue":"5","key":"10.1016\/j.annepidem.2026.110096_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.arcmed.2019.08.009","article-title":"Atherogenic index of plasma: novel predictive biomarker for cardiovascular illnesses","volume":"50","author":"Fernandez-Macias","year":"2019","journal-title":"Arch Med Res"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12944-020-01208-8","article-title":"The sensibility of the new blood lipid indicator--atherogenic index of plasma (AIP) in menopausal women with coronary artery disease","volume":"19","author":"Guo","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.annepidem.2026.110096_bib11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.advms.2021.09.003","article-title":"The predictive value of atherogenic index of plasma in the prediction of cardiovascular events; a fifteen-year cohort study","volume":"66","author":"Sadeghi","year":"2021","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.annepidem.2026.110096_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2021.03.009","article-title":"Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors","volume":"324","author":"Won","year":"2021","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.annepidem.2026.110096_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/children10040641","article-title":"Atherogenic Index of Plasma (AIP) and its association with fatty liver in obese adolescents","volume":"10","author":"Dag","year":"2023","journal-title":"Child"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib14","doi-asserted-by":"crossref","first-page":"9900","DOI":"10.1038\/s41598-021-89307-z","article-title":"Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12944-018-0656-1","article-title":"Atherogenic index of plasma is an effective index for estimating abdominal obesity","volume":"17","author":"Shen","year":"2018","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12944-018-0686-8","article-title":"Atherogenic index of plasma is a novel and better biomarker associated with obesity: a population-based cross-sectional study in China","volume":"17","author":"Zhu","year":"2018","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12876-024-03190-2","article-title":"Using new indices to predict metabolism dysfunction-associated fatty liver disease (MAFLD): analysis of the national health and nutrition examination survey database","volume":"24","author":"Li","year":"2024","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40001-022-00731-x","article-title":"Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes","volume":"27","author":"Samimi","year":"2022","journal-title":"Eur J Med Res"},{"issue":"2","key":"10.1016\/j.annepidem.2026.110096_bib19","first-page":"384","article-title":"The association between atherogenic index of plasma and metabolic dysfunction-associated fatty liver disease as detected by FibroScan","volume":"41","author":"Wang","year":"2024","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.annepidem.2026.110096_bib20","article-title":"Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017-2018","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol"},{"issue":"36","key":"10.1016\/j.annepidem.2026.110096_bib21","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.3748\/wjg.v28.i36.5364","article-title":"Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease","volume":"28","author":"Duan","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12944-020-01319-2","article-title":"The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study","volume":"19","author":"Dong","year":"2020","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.annepidem.2026.110096_bib23","article-title":"The atherogenic index of plasma: A novel factor more closely related to non-alcoholic fatty liver disease than other lipid parameters in adults","volume":"9","author":"Liu","year":"2022","journal-title":"Front Nutr"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12933-021-01342-2","article-title":"Association between triglyceride-glucose index and risk of arterial stiffness: a cohort study","volume":"20","author":"Wu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.annepidem.2026.110096_bib25","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110096_bib26","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12933-025-02941-z","article-title":"Association between atherogenic index of plasma (AIP) and all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a cohort study based on NHANES 1999-2018","volume":"24","author":"Gan","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.annepidem.2026.110096_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1579879","article-title":"Association between eGDR and MASLD and liver fibrosis: a cross-sectional study based on NHANES 2017-2023","volume":"12","author":"Peng","year":"2025","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.annepidem.2026.110096_bib29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1055\/s-0038-1633908","article-title":"Annoyance from multiple transportation noise: statistical models and outlier detection","volume":"43","author":"Kuhnt","year":"2004","journal-title":"Methods Inf Med"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110096_bib30","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S2215-0366(16)00097-3","article-title":"10-year trajectories of depressive symptoms and risk of dementia: a population-based study","volume":"3","author":"Mirza","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.annepidem.2026.110096_bib31","article-title":"Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12959-023-00542-y","article-title":"Longitudinal trajectories of atherogenic index of plasma and risks of cardiovascular diseases: results from the Korean genome and epidemiology study","volume":"21","author":"Chun","year":"2023","journal-title":"Thromb J"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12933-024-02449-y","article-title":"Exposure of cumulative atherogenic index of plasma and the development of prediabetes in middle-aged and elderly individuals: evidence from the CHARLS cohort study","volume":"23","author":"Zou","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/10641963.2024.2303999","article-title":"The positive association between the atherogenic index of plasma and the risk of new-onset hypertension: a nationwide cohort study in China","volume":"46","author":"Yuan","year":"2024","journal-title":"Clin Exp Hypertens"},{"issue":"6","key":"10.1016\/j.annepidem.2026.110096_bib35","article-title":"Atherogenic Index of Plasma (AIP): the most accurate indicator of overweight and obesity among lipid indices in type 2 diabetes-findings from a cross-sectional study","volume":"7","author":"Karimpour","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-025-02619-6","article-title":"Baseline atherogenic index of plasma and its trajectory predict onset of type 2 diabetes in a health screened adult population: a large longitudinal study","volume":"24","author":"Sun","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12933-023-02108-8","article-title":"Evaluation of the role of atherogenic index of plasma in the reversion from Prediabetes to normoglycemia or progression to Diabetes: a multi-center retrospective cohort study","volume":"23","author":"Yang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.annepidem.2026.110096_bib38","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3390\/jcm15031301","article-title":"The Role of Sex Hormone-Binding Globulin (SHBG) as a marker of metabolic dysfunction-associated steatotic liver disease, with an extended analysis in both men and women","volume":"15","author":"Fodor Duric","year":"2026","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13293-020-00344-1","article-title":"Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism","volume":"12","author":"Yan","year":"2021","journal-title":"Biol Sex Differ"},{"issue":"12","key":"10.1016\/j.annepidem.2026.110096_bib40","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/jc.2006-0587","article-title":"Review: The role of insulin resistance in nonalcoholic fatty liver disease","volume":"91","author":"Utzschneider","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.annepidem.2026.110096_bib41","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1073\/pnas.0630588100","article-title":"Triglyceride accumulation protects against fatty acid-induced lipotoxicity","volume":"100","author":"Listenberger","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.annepidem.2026.110096_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.annepidem.2026.110096_bib43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2013.12.013","article-title":"Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?","volume":"233","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.annepidem.2026.110096_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11892-002-0086-2","article-title":"Skeletal muscle triglyceride: marker or mediator of obesity-induced insulin resistance in type 2 diabetes mellitus?","volume":"2","author":"Goodpaster","year":"2002","journal-title":"Curr Diab Rep"},{"issue":"5","key":"10.1016\/j.annepidem.2026.110096_bib45","first-page":"325","article-title":"The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis","volume":"7","author":"Ginsberg","year":"2000","journal-title":"J Cardiovasc Risk"},{"issue":"10","key":"10.1016\/j.annepidem.2026.110096_bib46","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3949\/ccjm.75.10.721","article-title":"Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome","volume":"75","author":"Kim","year":"2008","journal-title":"Cleve Clin J Med"},{"issue":"7","key":"10.1016\/j.annepidem.2026.110096_bib47","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.annepidem.2026.110096_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101349","article-title":"The hepatocyte IKK:NF-kappaB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis","volume":"54","author":"Heida","year":"2021","journal-title":"Mol Metab"},{"issue":"10","key":"10.1016\/j.annepidem.2026.110096_bib49","article-title":"A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease","volume":"5","author":"Hammoutene","year":"2023","journal-title":"JHEP Rep"},{"issue":"20","key":"10.1016\/j.annepidem.2026.110096_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202200742","article-title":"Hepatic MDM2 causes metabolic associated fatty liver disease by blocking triglyceride-VLDL secretion via ApoB degradation","volume":"9","author":"Lin","year":"2022","journal-title":"Adv Sci"}],"container-title":["Annals of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047279726000943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047279726000943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:53:21Z","timestamp":1778795601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1047279726000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"alternative-id":["S1047279726000943"],"URL":"https:\/\/doi.org\/10.1016\/j.annepidem.2026.110096","relation":{},"ISSN":["1047-2797"],"issn-type":[{"value":"1047-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal atherogenic index of plasma trajectories and risk of MASLD progression: A large retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Annals of Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annepidem.2026.110096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110096"}}